BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

VTGN

Vistagen Therapeutics, Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Mar

Revenue, quarterly

$1M+504.9% year on year
$2M$1M$0−$1M
Q2 ’22Q3 ’23Q4 ’24Q4 ’25Q1 ’27
Company filings · 10-Q filed 14 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com

Cash and cash equivalents, quarter-end

$17M−65.3% year on year
$150M$100M$50M$0
Q2 ’22Q3 ’23Q4 ’24Q4 ’25Q1 ’27
Company filings · 10-Q filed 14 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$58M
$25M$0−$25M−$50M−$75M
Q4 ’18Q1 ’20Q2 ’21Q2 ’22Q3 ’23
Company filings · 10-Q filed 13 Feb 2024 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty